- Home
- VCYT
VCYT
Veracyte Inc.
as of 01-20-2026 3:53pm EST
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.9B | IPO Year: | 2013 |
| Target Price: | $46.00 | AVG Volume (30 days): | 670.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $22.61 - $50.71 | Next Earning Date: | 02-23-2026 |
| Revenue: | $495,141,000 | Revenue Growth: | 16.41% |
| Revenue Growth (this year): | 16.46% | Revenue Growth (next year): | 11.37% |
AI-Powered VCYT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Veracyte Inc. (VCYT)
SVP, General Counsel
Avg Cost/Share
$43.40
Shares
10,739
Total Value
$463,203.60
Owned After
67,860
Director
Avg Cost/Share
$45.65
Shares
20,000
Total Value
$908,923.34
Owned After
27,162
Chief Financial Officer
Avg Cost/Share
$46.93
Shares
13,278
Total Value
$621,955.21
Owned After
109,496
Chief Executive Officer
Avg Cost/Share
$47.12
Shares
7,668
Total Value
$361,075.59
Owned After
321,823
SVP, General Counsel
Avg Cost/Share
$47.30
Shares
1,422
Total Value
$67,260.78
Owned After
67,860
Chief Commercial Officer-CLIA
Avg Cost/Share
$47.51
Shares
1,278
Total Value
$60,717.78
Owned After
82,113
SEC Form 4
Chief Commercial Officer-CLIA
Avg Cost/Share
$50.00
Shares
2,808
Total Value
$140,400.00
Owned After
82,113
SEC Form 4
Director
Avg Cost/Share
$50.25
Shares
1,106
Total Value
$55,575.73
Owned After
29,362
SEC Form 4
Director
Avg Cost/Share
$42.21
Shares
10,000
Total Value
$423,563.05
Owned After
35,708
VP, Chief Accounting Officer
Avg Cost/Share
$42.33
Shares
5,102
Total Value
$215,978.37
Owned After
38,745
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| McGuire Annie | VCYT | SVP, General Counsel | Dec 16, 2025 | Sell | $43.40 | 10,739 | $463,203.60 | 67,860 | |
| EASTHAM KARIN | VCYT | Director | Dec 5, 2025 | Sell | $45.65 | 20,000 | $908,923.34 | 27,162 | |
| Chambers Rebecca | VCYT | Chief Financial Officer | Dec 4, 2025 | Sell | $46.93 | 13,278 | $621,955.21 | 109,496 | |
| Stapley Marc | VCYT | Chief Executive Officer | Dec 4, 2025 | Sell | $47.12 | 7,668 | $361,075.59 | 321,823 | |
| McGuire Annie | VCYT | SVP, General Counsel | Dec 4, 2025 | Sell | $47.30 | 1,422 | $67,260.78 | 67,860 | |
| Leite John | VCYT | Chief Commercial Officer-CLIA | Dec 4, 2025 | Sell | $47.51 | 1,278 | $60,717.78 | 82,113 | |
| Leite John | VCYT | Chief Commercial Officer-CLIA | Nov 25, 2025 | Sell | $50.00 | 2,808 | $140,400.00 | 82,113 | |
| JONES EVAN/ FA | VCYT | Director | Nov 25, 2025 | Sell | $50.25 | 1,106 | $55,575.73 | 29,362 | |
| Holstein Jens | VCYT | Director | Nov 20, 2025 | Sell | $42.21 | 10,000 | $423,563.05 | 35,708 | |
| Wygant Jonathan | VCYT | VP, Chief Accounting Officer | Nov 10, 2025 | Sell | $42.33 | 5,102 | $215,978.37 | 38,745 |
Compare VCYT vs Leading Stocks
See how VCYT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "VCYT Veracyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.